|The Evolving Standard of Care in Relapsed/Refractory Multiple Myeloma|
Paul G. Richardson, MD
|Release Date: December 14, 2017|
Expiration Date: December 14, 2018
The advent of new therapeutic strategies in relapsed/refractory multiple myeloma (RRMM) has impacted the standard of care in clinical practice. With the potential for major changes to existing clinical recommendations, health care providers who treat patients with multiple myeloma must be prepared for implementation into practice. In this activity, participants will learn about the current treatment paradigms in RRMM and the new drug regimens that are being used as the standard of care in clinical practice. In addition, participants will gain an understanding of the potential impact of investigational therapies on the standard of care in relapsed/refractory disease.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|